



COLORADO

Department of Health Care
Policy & Financing

AGENDA

Pharmaceutics & Therapeutics Committee

Department of Health Care Policy & Financing

Zoom Webinar

Registration: https://magellanhealth.zoom.us/webinar/register/WN_KOo9--iJQVOuqbouXRAzYw

Tuesday, January 11, 2022, 1:00-5:00 P.M.

1. Committee Member Introductions

2. Unfinished Business and General Orders

Approval of minutes from October 12, 2021 P&T meeting

Updates from October 12, 2021 P&T Meeting

Review of Hepatitis C Virus Treatments - Direct-Acting Antivirals (DAAs)

Review of Human Immunodeficiency Virus Treatments, Oral

Pulmonary Arterial Hypertension (PAH) Therapies

- Phosphodiesterase Inhibitors
- Endothelin Antagonists
- Prostanoids
- Guanylate Cyclase (sGC) Stimulators

Review of Antidepressants - Newer Generation Agents

Review of Antiemetics - Oral & Non-Oral

Review of H. Pylori Treatments

Review of Targeted Immune Modulators

Review of Respiratory Agents

- Inhaled Anticholinergics & Combinations
- Short-Acting & Long-Acting Beta-Agonists (SABAs & LABAs)
- Inhaled Corticosteroids & Combinations

Mass review drug classes:

Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) - Oral & Non-Oral

Antibiotics, Inhaled

Anti-herpetic Agents - Oral & Topical

Fluoroquinolones, Oral

Hepatitis C Virus Treatments - Ribavirin Products

Antidepressants

- Monoamine Oxidase Inhibitors (MAOIs)
- Tricyclics

Triptans, Ditans and Other Migraine Agents - Oral & Non-Oral

Antipsoriatics - Oral & Topical



Topical Immunomodulators
 Topical Steroids - Low, Medium, High & Very High Potencies
 Pancreatic Enzymes
 Proton Pump Inhibitors (PPIs)
 Non-Biologic Ulcerative Colitis Agents - Oral & Rectal
 Immune Globulins
 Newer Generation Antihistamines
 Antihistamine/Decongestant Combinations
 Intranasal Rhinitis Agents
 Leukotriene Modifiers
 Methotrexate Products
 Epinephrine Products
 Newer Hereditary Angioedema (HAE) Agents
 Antihyperuricemics
 Respiratory Agents - Phosphodiesterase Inhibitors (PDEIs)

3. New Business

Updates from the Prior Authorization Call Center

4. Drug Classes Up for Review

Review of Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) - Oral & Non-Oral
 Review of Beta-Blockers & Combinations*
 Review of Anticonvulsants, Oral
 Review of Newer Generation Antidepressants
 Review of Anti-Parkinson's Agents
 Review of Benzodiazepines (Non-Sedative Hypnotic)
 Review of Atypical Antipsychotics - Oral & Topical
 Review of Calcitonin Gene-Related Peptide Inhibitors (CGRPIs)
 Review of Triptans, Ditans and Other Migraine Treatments - Oral & Non-Oral
 Review of Skeletal Muscle Relaxants
 Review of Stimulants and Related Agents
 Review of Growth Hormones
 Review of Bile Salts
 Review of Multiple Sclerosis
 Review of Ophthalmics, Anti-Inflammatories*

* *Removed from Mass Review*

Mass review drug classes:

- Non-Opioid Analgesia Agents - Oral & Topical
- Opioids - Short-Acting, Fentanyl Preparations & Long-Acting
- Alpha-Blockers & Calcium Channel Blockers
- Lipotropics - Bile Acid Sequestrants, Fibrates, Other

Improving health care equity, access and outcomes for the people we serve while
 saving Coloradans money on health care and driving value for Colorado.
www.colorado.gov/hcpf



- Statins & Combinations
- Monoamine Oxidase Inhibitors (MAOIs)
- Tricyclic Antidepressants
- Anxiolytics, Non-Benzodiazepine
- Lithium Agents
- Neurocognitive Disorder Agents
- Sedative Hypnotics - Non-Benzodiazepine & Benzodiazepine
- Skeletal Muscle Relaxants
- Hemorrhoidal, Anorectal, and Related Topical Anesthetic Agents
- Ophthalmics, Allergy
- Ophthalmics, Immunomodulators
- Ophthalmics, Glaucoma

Each Review will contain:

- Oral presentation by manufacturers, providers, and public Gro
- Overview for each Drug Class, including market share overview
- Committee Discussion and Recommendations for each Class

Mass Review drug classes will only include:

- Overview for each Drug Class, including market share overview

Presentations:

- Interested parties who want to present at the meeting shall give advanced notice and provide a one-page summary of the clinical testimony that will be presented for P&T Committee dissemination.
- Advance notice requests to present and/or written public comments can be submitted to Jessica Czechowski, Pharmacist Account Executive, jlczechowski@magellanhealth.com and carbon copy: Brittany Schock, PDL Pharmacist, brittany.schock@state.co.us. Once approved, public comments will be distributed to P&T Committee Members. Due to Virtual venue change, requests and public comment summaries are due by **December 31th, 2021 by 5pm MST**.

5. Adjourn

Upcoming Meeting Date: April 12, 2022.

Reasonable accommodations will be provided upon request. Auxiliary aids and services for individuals with disabilities and language services for individuals whose first language is not English may be provided upon request. Please notify the [504/ADA Coordinator](#) or hcpf504ada@state.co.us at least one week prior to the meeting to make arrangements.

